13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q3 2021. See the latest, Q2 2026 →
Reported value
$4.22B
−14% on the quarter before
Positions
43
10 new · 3 sold out
Top 10
84.4%
of the value
Est. gain
−$515.7M
on stocks held all quarter
Est. return
−13.3%
on those stocks since Q2 2021
Positions as of Sep 30, 2021, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2021. Striped tiles are options.
Largest buys
Since Q2 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Robinhood~$323.9MNew · 0.0% → 7.7%+7,697,335 shares
- Adagio Therapeutics Inc~$240.0MNew · 0.0% → 5.7%+5,680,785 shares
- Duolingo Inc.~$118.5MNew · 0.0% → 2.8%+712,304 shares
- Benson Hill Inc~$105.2MNew · 0.0% → 2.5%+14,752,271 shares
- Illumina Inc~$21.7MNew · 0.0% → 0.5%+53,470 shares
- Tenaya Therapeutics Inc~$18.9MNew · 0.0% → 0.4%+915,705 shares
- Amplitude Inc~$10.3MNew · 0.0% → 0.2%+189,447 shares
- Tscan Therapeutics Inc~$9.0MNew · 0.0% → 0.2%+1,077,080 shares
- Invitae Corp~$6.1MNew · 0.0% → 0.1%+215,965 shares
- Exact Sciences Corp~$2.2MNew · 0.0% → 0.1%+23,205 shares
Largest sells
Since Q2 2021, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- UiPath~$602.1MCut · 40.2% → 21.9%−11,444,357 shares
- Airbnb~$80.5MSold out · 1.6% → 0.0%−525,626 shares
- Slack Technologies Inc.~$57.6MSold out · 1.2% → 0.0%−1,299,771 shares
- Clover Health Investments Co~$54.8MSold out · 1.1% → 0.0%−4,113,742 shares
- Beam Therapeutics Inc~$27.3MCut · 1.7% → 0.7%−313,982 shares
- Arcus Biosciences Inc~$17.9MCut · 2.6% → 3.4%−513,343 shares
- Relay Therapeutics Inc~$5.8MCut · 1.4% → 1.2%−185,379 shares
- Rapt Therapeutics Inc~$2.4MCut · 0.5% → 0.5%−78,563 shares
Holdings
As of Sep 30, 2021. Changes are in shares against Jun 30, 2021, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UiPathCL A · shares −39% · price −22.6% | 21.9% | $925.0M | −$269.3M | ||||||||
| Verve Therapeutics IncCOM · shares 0% · price −22.0% | 12.2% | $515.8M | −$145.4M | ||||||||
| Dexcom IncCOM · shares 0% · price +28.0% | 10.4% | $440.5M | +$96.4M | ||||||||
| Oscar Health IncCL A · shares 0% · price −19.1% | 9.9% | $418.1M | −$98.8M | ||||||||
| Lyft IncCL A COM · shares 0% · price −11.4% | 7.8% | $328.9M | −$42.3M | ||||||||
| RobinhoodCOM CL A · shares New | 7.7% | $323.9M | — | ||||||||
| Adagio Therapeutics IncCOM · shares New | 5.7% | $240.0M | — | ||||||||
| Arcus Biosciences IncCOM · shares −11% · price +27.0% | 3.4% | $143.0M | +$30.4M | ||||||||
| Duolingo Inc.CL A COM · shares New | 2.8% | $118.5M | — | ||||||||
| Benson Hill IncCOMMON STOCK · shares New | 2.5% | $105.2M | — | ||||||||
| Lyell Immunopharma IncCOM · shares 0% · price −8.9% | 2.1% | $86.8M | −$8.4M | ||||||||
| Desktop Metal IncCOM CL A · shares 0% · price −37.7% | 1.9% | $79.2M | −$47.8M | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price +14.5% | 1.5% | $63.3M | +$8.0M | ||||||||
| Relay Therapeutics IncCOM · shares −10% · price −13.8% | 1.2% | $51.8M | −$8.3M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares 0% · price −1.9% | 0.77% | $32.6M | −$615,000 | ||||||||
| Kronos Bio IncCOM · shares 0% · price −12.5% | 0.72% | $30.1M | −$4.3M | ||||||||
| Beam Therapeutics IncCOM · shares −49% · price −32.4% | 0.66% | $28.0M | −$13.4M | ||||||||
| Vaccitech PlcADS · shares 0% · price −6.2% | 0.64% | $26.8M | −$1.8M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price −25.6% | 0.58% | $24.3M | −$8.3M | ||||||||
| Rapt Therapeutics IncCOM · shares −10.0% · price −2.3% | 0.52% | $22.1M | −$525,519 | ||||||||
| Illumina IncCOM · shares New | 0.51% | $21.7M | — | ||||||||
| Ideaya Biosciences IncCOM · shares 0% · price +21.4% | 0.46% | $19.2M | +$3.4M | ||||||||
| Tenaya Therapeutics IncCOM · shares New | 0.45% | $18.9M | — | ||||||||
| Cortexyme IncCOM · shares 0% · price +72.9% | 0.41% | $17.3M | +$7.3M | ||||||||
| Vera Therapeutics IncCL A · shares 0% · price +30.8% | 0.39% | $16.4M | +$3.9M | ||||||||
| Total · 43 positions | 100% | $4.22B | −$515.7M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2021 to Q3 2021: 33 stocks held throughout, down $515.7M (−13.3%).
- Dexcom Inc+$96.4M+28%
- Arcus Biosciences Inc+$30.4M+27%
- Sana Biotechnology Inc+$8.0M+15%
- Cortexyme Inc+$7.3M+73%
- Spero Therapeutics Inc+$4.0M+32%
- Lyft Inc−$42.3M−11%
- Desktop Metal Inc−$47.8M−38%
- Oscar Health Inc−$98.8M−19%
- Verve Therapeutics Inc−$145.4M−22%
- UiPath−$269.3M−23%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |